Unicycive Therapeutics Inc. Company Profile
NASDAQ: UNCYHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Unicycive Therapeutics at a glance
Unicycive Therapeutics Inc. (NASDAQ: UNCY) is a Biotechnology: Pharmaceutical Preparations company in the Health Care sector headquartered in Mountain View, CA. Unicycive Therapeutics is led by Dr. Shalabh K. Gupta M.D., MPA and employs about 21 people. The company's shares have traded publicly since 2021.
At a market capitalization of $113.4 million, it is considered a small-cap company. Its SEC Central Index Key (CIK) is 0001766140, which identifies the company's filings on EDGAR.
Summary generated from market data by MetaCap's automated system. Methodology
What does Unicycive Therapeutics do?
Unicycive Therapeutics, Inc., a clinical-stage biotechnology company, identifies, develops, and commercializes therapies for the treatment of kidney diseases in the United States. It develops oxylanthanum carbonate, a lanthanum-based phosphate binding agent, which is for the treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI-494, a nicotinamide ester derivative and a selective ATP-sensitive mitochondrial potassium channel activator, which is in Phase I clinical trial for the treatment of acute kidney injury and pre-clinical stage for the treatment of chronic kidney disease. The company was incorporated in 2016 and is headquartered in Mountain View, California.
Business description based on the company's public filings.
Company information
- Legal name
- Unicycive Therapeutics Inc.
- Ticker
- NASDAQ: UNCY
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Dr. Shalabh K. Gupta M.D., MPA
- Employees
- 21
- Headquarters
- 1975 West El Camino Real, Mountain View, CA, United States
- Phone
- 650 351 4495
- Website
- unicycive.com
- IPO year
- 2021
- Market cap
- $113.37M
- SEC CIK
- 0001766140
Companies similar to Unicycive Therapeutics
| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| QUCYQuantum Cyber N.V. | 1.35 | -2.88% | $113.49M | vs UNCY |
| RANIRani Therapeutics Holdings Inc. Class A | 0.799 | +0.88% | $112.28M | vs UNCY |
| PMVPPMV Pharmaceuticals Inc. | 1.52 | +2.01% | $114.78M | vs UNCY |
| IMUXImmunic Inc. | 8.19 | +8.33% | $111.75M | vs UNCY |
| GNLXGenelux Corporation | 2.56 | +2.40% | $115.83M | vs UNCY |
| COYACoya Therapeutics Inc. | 4.95 | -0.80% | $116.12M | vs UNCY |
| FHTXFoghorn Therapeutics Inc. | 2.00 | +0.50% | $118.77M | vs UNCY |
| INOInovio Pharmaceuticals Inc. | 1.15 | +5.50% | $118.91M | vs UNCY |